Contact

• workAcademic Unit Of Oncology,Division of Cancer and Stem Cells, City Hospital Campus
  Nottingham City Hospital
  Hucknall Road
  Nottingham
  NG5 1PB
  UK
• work01158231850
• fax01158231849
• srinivasan.madhusudan@nottingham.ac.uk

Biography

Professor Srinivasan Madhusudan trained in Medical Oncology at Oxford, England. As a Cancer Research UK Clinical Research Fellow he completed his Ph.D. work at the Weatherall Institute of Molecular Medicine, Oxford. In 2007, he moved to Nottingham as a Clinical Associate Professor in Medical Oncology. In 2011, he was awarded the prestigious 'Goulstonian Lectureship' by the Royal College of Physicians, London, an award made to the most academically outstanding Young Fellow of the College. In 2016, he was promoted to Professor of Medical Oncology. He served as the Head of Oncology at Nottingham University Hospitals from 2017-2020. As an academic oncologist, he is very active in cancer clinical trials. He has lead the Cancer Clinical Trials Unit at Nottingham University Hospitals and was previously the National Institute for Health Research (NIHR) Divisional Lead for Cancer (East Midlands).

Prof Madhusudan's pre-clinical laboratory research is focused on the evaluation of DNA repair factors as prognostic, predictive and therapeutic targets in cancer. Research in his laboratory has received funding from the Medical Research Council, Breast Cancer Now, Target Ovarian Cancer and Naaz-Coker Ovarian Cancer Research Fellowship. Graduate Research students his group are funded through various international scholarships. Prof Madhusudan's group has identified novel biomarkers, potential drug targets and newer approaches for personalized treatment strategies targeting DNA repair in cancer. Prof Madhusudan has published over 130 research articles, edited two books and contributed to several book chapters. In recognition of his outstanding translational cancer research, he was recently awarded the prestigious 'Lady Estelle Wolfson lectureship in Translational Medicine for 2019' by the Royal College of Physicians of London.

Expertise Summary

Clinical trials; DNA repair; translational oncology; biomarkers; drug discovery; breast cancers; upper GI cancers; ovarian cancers; brain tumours.

Research Summary

DNA repair targeted precision medicine strategies in cancers.

Selected Publications

• ARORA A, PARVATHANENI S, ALESKANDARANY MA, AGARWAL D, ALI R, ABDEL-FATAH TM, GREEN AR, BALL GR, RAKHA EA, ELLIS IO, SHARMA S and MADHUSUDAN S, 2016. Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers. Molecular cancer therapeutics. (In Press.)
• ALSUBHI N, MIDDLETON F, ABDEL-FATAH TMA, STEPHENS P, DOHERTY R, ARORA A, MOSELEY PM, CHAN SYT, ALESKANDARANY MA, GREEN AR, RAKHA EA, ELLIS IO, MARTIN SG, CURTIN NJ and MADHUSUDAN S, 2016. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer Molecular Oncology. 10(2), 213-223
• ARORA, A., ABDEL-FATAH, T. M., AGARWAL, D., DOHERTY, R., CROTEAU, D. L., MOSELEY, P. M., HAMEED, K., GREEN, A., ALESKANDARANY, M. A., RAKHA, E. A., PATTERSON, K., BALL, G., CHAN, S. Y., ELLIS, I. O., BOHR, V. A., BRYANT, H. E. and MADHUSUDAN, S., 2016. Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers: Carcinogenesis Carcinogenesis. 37(1), 63-71
• ARORA, A., AGARWAL, D., ABDEL-FATAH, T.M.A., LU, H., CROTEAU, D.L., MOSELEY, P., ALESKANDARANY, M.A., GREEN, A.R., BALL, G., RAKHA, E.A., CHAN, S.Y.T., ELLIS, I.O., WANG, L.L., ZHAO, Y., BALAJEE, A.S., BOHR, V.A. and MADHUSUDAN, S., 2016. RECQL4 helicase has oncogenic potential in sporadic breast cancers Journal of Pathology. 238(4), 495-501

• View all publications

Past Research

DNA repair targeted precision medicine strategies in cancers.

Future Research

DNA repair targeted precision medicine strategies in cancers.

• MIDDLETON G., PALMER DH, GREENHALF W, GHANEH P, JACKSON R, COX T, EVANS A, WADSLEY J, VALLE J, PROPPER D, WASAN H, FALK S, CUNNINGHAM D, COXON F, ROSS P, MADHUSUDAN S, WADD N, CORRIE P, HICKISH T, COSTELLO E, CAMPBELL F, RAWCLIFFE C, AND NEOPTOLEMOS J., 2017. A prospective, phase II, double blind multicentre randomised controlled trial comparing gemcitabine plus vandetanib with gemcitabine plus placebo in locally advanced or metastatic pancreatic cancer Lancet Oncology. 18(4), 486-499
• GREEN AR, ALESKANDARANY MA, ALI R, HODGSON EG, ATABANI S, DE SOUZA K, RAKHA EA, ELLIS IO and MADHUSUDAN S, 2017. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer immunology research. 5(4), 292-299
• NAIDOO K, WAI PT, MAGUIRE SL, DALEY F, HAIDER S, KRIPLANI D, CAMPBELL J, MIRZA H, GRIGORIADIS A, TUTT A, MOSELEY PM, ABDEL-FATAH TMA, CHAN SY, MADHUSUDAN S, RAKHA EA, ELLIS IO, LORD CJ, YUAN Y, GREEN AR and NATRAJAN R, 2017. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response Targeted Therapies in Breast Cancer. Molecular cancer therapeutics. (In Press.)
• SAVVA C, KAYE P, SOOMRO I, PARSONS SL, JAMES E and MADHUSUDAN S, 2017. Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center. Journal of gastrointestinal cancer. (In Press.)
• PARVATHANENI S, LU X, CHAUDHARY R, LAL A, MADHUSUDAN S and SHARMA S, 2017. RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner. Oncotarget. 8(44), 75924-75942
• REECE-SMITH AM, SAUNDERS JH, SOOMRO IN, BOWMAN CR, DUFFY JP, KAYE PV, WELCH NT, MADHUSUDAN S and PARSONS SL, 2017. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma. Annals of the Royal College of Surgeons of England. 99(5), 378-384
• ALSUBHI N, MIDDLETON F, ABDEL-FATAH TMA, STEPHENS P, DOHERTY R, ARORA A, MOSELEY PM, CHAN SYT, ALESKANDARANY MA, GREEN AR, RAKHA EA, ELLIS IO, MARTIN SG, CURTIN NJ and MADHUSUDAN S, 2016. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer Molecular Oncology. 10(2), 213-223
• ARORA, A., ABDEL-FATAH, T. M., AGARWAL, D., DOHERTY, R., CROTEAU, D. L., MOSELEY, P. M., HAMEED, K., GREEN, A., ALESKANDARANY, M. A., RAKHA, E. A., PATTERSON, K., BALL, G., CHAN, S. Y., ELLIS, I. O., BOHR, V. A., BRYANT, H. E. and MADHUSUDAN, S., 2016. Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers: Carcinogenesis Carcinogenesis. 37(1), 63-71
• SHAMANNA, R. A., LU, H., CROTEAU, D. L., ARORA, A., AGARWAL, D., BALL, G., ALESKANDARANY, M. A., ELLIS, I. O., POMMIER, Y., MADHUSUDAN, S. and BOHR, V. A., 2016. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer: Oncotarget Oncotarget.
• ARORA, A., AGARWAL, D., ABDEL-FATAH, T.M.A., LU, H., CROTEAU, D.L., MOSELEY, P., ALESKANDARANY, M.A., GREEN, A.R., BALL, G., RAKHA, E.A., CHAN, S.Y.T., ELLIS, I.O., WANG, L.L., ZHAO, Y., BALAJEE, A.S., BOHR, V.A. and MADHUSUDAN, S., 2016. RECQL4 helicase has oncogenic potential in sporadic breast cancers Journal of Pathology. 238(4), 495-501
• MO D, FANG H, NIU K, LIU J, WU M, LI S, ZHU T, ALESKANDARANY MA, ARORA A, LOBO DN, MADHUSUDAN S, BALAJEE AS, CHI Z, ZHAO Y, 2016. Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway. Cancer Research. 15(76), 10
• ALSHAREEDA AT, NEGM OH, ALESKANDARANY MA, GREEN AR, NOLAN C, TIGHHE PJ, MADHUSUDAN S, ELLIS IO and RAKHA EA, 2016. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast cancer research and treatment. 159(1), 41-53
• ARORA A, PARVATHANENI S, ALESKANDARANY MA, AGARWAL D, ALI R, ABDEL-FATAH TM, GREEN AR, BALL GR, RAKHA EA, ELLIS IO, SHARMA S and MADHUSUDAN S, 2016. Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers. Molecular cancer therapeutics. (In Press.)
• BRIDGEWATER J, LOPES A, PALMER D, CUNNINGHAM D, ANTHONEY A, MARAVEYAS A, MADHUSUDAN S, IVESON T, VALLE J and WASAN H, 2016. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. British journal of cancer. 114(9), 965-71
• MO D, FANG H, NIU K, LIU J, WU M, LI S, ZHU T, ALESKANDARANY MA, ARORA A, LOBO DN, MADHUSUDAN S, BALAJEE AS, CHI Z and ZHAO Y, 2016. Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway. Cancer research. 76(10), 3057-66
• ALI R, RAKHA EA, MADHUSUDAN S and BRYANT HE, 2016. DNA damage repair in breast cancer and its therapeutic implications. Pathology. 49(2), 156-165
• ARORA A, ABDEL-FATAH TMA, AGARWAL D, DOHERTY R, MOSELEY PM, ALESKANDARANY MA, GREEN AR, BALL G, ALSHAREEDA AT, RAKHA EA, CHAN SYT, ELLIS IO and MADHUSUDAN S, 2015. Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. Molecular cancer therapeutics. 14(4), 1057-65
• ABDEL-FATAH TMA, MIDDLETON FK, ARORA A, AGARWAL D, CHEN T, MOSELEY PM, PERRY C, DOHERTY R, CHAN S, GREEN AR, RAKHA E, BALL G, ELLIS IO, CURTIN NJ and MADHUSUDAN S, 2015. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Molecular oncology. 9(3), 569-85
• ALBARAKATI, NADA, ABDEL-FATAH, TAREK M. A., DOHERTY, RACHEL, RUSSELL, ROSLIN, AGARWAL, DEVIKA, MOSELEY, PAUL, PERRY, CHRISTINA, ARORA, ARVIND, ALSUBHI, NOUF, SEEDHOUSE, CLAIRE, RAKHA, EMAD A., GREEN, ANDREW, BALL, GRAHAM, CHAN, STEPHEN, CALDAS, CARLOS, ELLIS, IAN O. and MADHUSUDAN, SRINIVASAN, 2015. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy MOLECULAR ONCOLOGY. 9(1), 204-217
• ABDEL-FATAH TM, ARORA A, MOSELEY PM, PERRY C, RAKHA EA, GREEN AR, CHAN SY, ELLIS IO, MADHUSUDAN S., 2015. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget. 6(26), 21964-78.
• VALLE JW, WASAN H, LOPES A, BACKEN AC, PALMER DH, MORRIS K, DUGGAN M, CUNNINGHAM D, ANTHONEY DA, CORRIE P, MADHUSUDAN S, MARAVEYAS A, ROSS PJ, WATERS JS, STEWARD WP, REES C, BEARE S, DIVE C, BRIDGEWATER JA., 2015. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncology. 2015 Aug;. 16(8), 967-78.
• FORD HER, MARSHALL A, BRIDGEWATER JA, JANOWITZ T, COXON FY, WADSLEY J, MANSOOR W, FYFE D, MADHUSUDAN S, MIDDLETON GW, SWINSON D, FALK S, CHAU I, CUNNINGHAM D, KARECLAS P, COOK N, BLAZEBY JM, DUNN JA and COUGAR-02 INVESTIGATORS, 2014. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet oncology. 15(1), 78-86
• ABDEL-FATAH TMA, RUSSELL R, MALONEY DJ, MOHAN M , DORJSUREN D, RUEDA OM, MOSELEY P, MUKHERJEE A , JADHAV A, SIMEONOV A, WILSON DM III , BALL G, CHAN S, CALDAS C, ELLIS IO, AND MADHUSUDAN S., 2014. Genomic and protein expression analysis reveals Flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer . Molecular Oncology 8(7), 1326-38.
• PERRY,C, PERRY,C, AGARWAL,D, ABDEL FATAH,T, LOURDUSAMY,A, GRUNDY,R, AUER,D, LAKHANI,R, WALKER,D, SCOTT,I, CHAN,S, MADHUSTANI,S and BALL,G, 2014. Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era Oncotarget. 5(14), 5764-5781
• ALBARAKATI N, ABDEL-FATAH TMA, DOHERTY R, RUSSELL R, AGARWAL D, MOSELEY P, PERRY C, ARORA A, ALSUBHI N, SEEDHOUSE C, RAKHA EA, GREEN A, BALL G, CHAN S, CALDAS C, ELLIS IO and MADHUSUDAN S, 2014. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Molecular oncology. 9(1), 204-17
• ABDEL-FATAH TM, PERRY C, ARORA A, THOMPSON N, DOHERTY R, MOSELEY PM, GREEN AR, CHAN SY, ELLIS IO and MADHUSUDAN S, 2014. Is there a role for base excision repair in estrogen driven breast cancers? Antioxidants & redox signaling. (In Press.)
• ABDEL-FATAH T, ARORA A, AGARWAL D, MOSELEY P, PERRY C, THOMPSON N, GREEN AR, RAKHA E, CHAN S, BALL G, ELLIS IO and MADHUSUDAN S, 2014. Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. Breast cancer research and treatment. 146(2), 309-20
• MIDDLETON G, SILCOCKS P, COX T, VALLE J, WADSLEY J, PROPPER D, COXON F, ROSS P, MADHUSUDAN S, ROQUES T, CUNNINGHAM D, FALK S, WADD N, HARRISON M, CORRIE P, IVESON T, ROBINSON A, MCADAM K, EATOCK M, EVANS J, ARCHER C, HICKISH T, GARCIA-ALONSO A, NICOLSON M, STEWARD W, ANTHONEY A, GREENHALF W, SHAW V, COSTELLO E, NAISBITT D, RAWCLIFFE C, NANSON G and NEOPTOLEMOS J, 2014. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology. 15(8), 829-40
• ADHIKAREE J and MADHUSUDAN S, 2014. Is there a role for second-line platinum re-challenge in advanced biliary tract cancers? Medical oncology (Northwood, London, England). 31(7), 46
• ABDEL-FATAH TMA, RUSSELL R, ALBARAKATI N, MALONEY DJ, DORJSUREN D, RUEDA OM, MOSELEY P, MOHAN V, SUN H, ABBOTTS R, MUKHERJEE A, AGARWAL D, ILLUZZI JL, JADHAV A, SIMEONOV A, BALL G, CHAN S, CALDAS C, ELLIS IO, WILSON DM and MADHUSUDAN S, 2014. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Molecular oncology. (In Press.)
• ABBOTTS R, JEWELL R, NSENGIMANA J, MALONEY DJ, SIMEONOV A, SEEDHOUSE C, ELLIOTT F, LAYE J, WALKER C, JADHAV A, GRABOWSKA A, BALL G, PATEL PM, NEWTON-BISHOP J, WILSON DM and MADHUSUDAN S, 2014. Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget. 5(10), 3273-86
• ABDEL-FATAH, T. M., PERRY, C., ARORA, A., THOMPSON, N., DOHERTY, R., MOSELEY, P. M., GREEN, A. R., CHAN, S. Y., ELLIS, I. O. and MADHUSUDAN, S., 2014. Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?: Antioxid Redox Signal Antioxid Redox Signal. 21(16), 2262-8
• TEWARI N, ZAITOUN AM, ARORA A, MADHUSUDAN S, ILYAS M and LOBO DN, 2013. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. BMC cancer. 13, 436
• ZHANG, JIHONG, STEVENS, MALCOLM F G, LAUGHTON, CHARLES A, MADHUSUDAN, SRINIVASAN and BRADSHAW, TRACEY D, 2010. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology. 78(2), 103-14